Sosei lands $200M to fund six Heptares’ programs, including dementia

LONDON – Sosei Group Corp. has raised $200 million in a placing to fund clinical development of proprietary assets discovered by its U.K. subsidiary, G protein-coupled receptor (GPCR) specialist Heptares Therapeutics.

The transaction, structured as an international-only offering, was one of the biggest biopharmaceutical offering out of Japan since 2011.